Eplerenone

Generic Name: Eplerenone

Brand Names: Inspra

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₃₀O_₆

CAS Number: 107724-20-9

Unique Ingredient Identifier: 6995V82D0B

Background: Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.

Indication: For improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.

Associated Conditions: Hypertension, LVEF <40% Congestive heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class II)

Associated Therapies: -

Clinical Trials

Vascular Effects of High-Salt After Preeclampsia

Early Phase 1

Recruiting

Conditions: Preeclampsia
Preeclampsia Postpartum

Interventions: Drug: Eplerenone

First Posted Date: 2024-12-27

Last Posted Date: 2025-01-06

Lead Sponsor: Anna Stanhewicz, PhD

Target Recruit Count: 40

Registration Number: NCT06749418

Locations: 🇺🇸
University of Iowa, Iowa City, Iowa, United States

Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects

Phase 1

Completed

Conditions: Pharmacodynamic

Interventions: Drug: Fludrocortisone
Drug: Vamorolone
Drug: Eplerenone

First Posted Date: 2024-10-18

Last Posted Date: 2024-10-18

Lead Sponsor: Santhera Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT06649409

Locations: 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany

Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease

Phase 4

Not yet recruiting

Conditions: Paroxysmal Atrial Fibrillation

Interventions: Drug: Eplerenone

First Posted Date: 2023-12-13

Last Posted Date: 2023-12-13

Lead Sponsor: Assiut University

Target Recruit Count: 100

Registration Number: NCT06168994

Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension

Phase 4

Recruiting

Conditions: Hypertension
Left Ventricular Hypertrophy

Interventions: Drug: Eplerenone
Drug: Chlorthalidone
Drug: Potassium

First Posted Date: 2022-10-25

Last Posted Date: 2024-12-16

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 75

Registration Number: NCT05593055

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Eplerenone Versus PDT: Comparative Study by OCTA

Completed

Conditions: Central Serous Chorioretinopathy

Interventions: Device: The patients underwent half fluence photodynamic therapy for 6 months
Drug: Eplerenone

First Posted Date: 2021-11-02

Last Posted Date: 2021-11-02

Lead Sponsor: Federico II University

Target Recruit Count: 30

Registration Number: NCT05104138

Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study

Phase 4

Recruiting

Conditions: Primary Aldosteronism
Hypertension

Interventions: Drug: Eplerenone

First Posted Date: 2021-09-01

Last Posted Date: 2023-02-27

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 40

Registration Number: NCT05030545

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

MR Antagonist and LSD1

Phase 4

Recruiting

Conditions: Hypertension
Mineralocorticoid Excess

Interventions: Drug: Amlodipine
Drug: Eplerenone

First Posted Date: 2021-04-12

Last Posted Date: 2024-08-09

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 300

Registration Number: NCT04840342

Locations: 🇺🇸
Brigham and Women's, Boston, Massachusetts, United States

Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity

Phase 4

Recruiting

Conditions: Hypertension
Overweight and Obesity
Metabolic Syndrome

Interventions: Drug: Chlorthalidone with potassium chloride
Drug: Eplerenone

First Posted Date: 2020-08-19

Last Posted Date: 2023-11-14

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 80

Registration Number: NCT04519164

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists)

Phase 2

Terminated

Conditions: Vitreomacular Traction
Subretinal Edema

Interventions: Drug: Eplerenone

First Posted Date: 2020-03-09

Last Posted Date: 2021-01-08

Lead Sponsor: Wagner Macula & Retina Center

Target Recruit Count: 2

Registration Number: NCT04300881

Locations: 🇺🇸
Wagner Macula & Retina Center, Norfolk, Virginia, United States

A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart Failure

Phase 4

Conditions: Systolic Heart Failure

Interventions: Drug: Spironolactone
Drug: Eplerenone

First Posted Date: 2019-06-13

Last Posted Date: 2023-02-01

Lead Sponsor: Bispebjerg Hospital

Target Recruit Count: 7200

Registration Number: NCT03984591

Locations: 🇩🇰
Bispebjerg Hospital, Copenhagen, Denmark

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy